BridgeBio Oncology Therapeutics, Inc (BBOT) vs Prelude Therapeutics Incorporated (PRLD)

BridgeBio Oncology Therapeutics, Inc and Prelude Therapeutics Incorporated are both Biotechnology companies. BridgeBio Oncology Therapeutics, Inc and Prelude Therapeutics Incorporated are of similar size ($319.9M and $318.4M). BridgeBio Oncology Therapeutics, Inc has the higher net margin (0.00% vs −269.8%) and the lower return on invested capital (−127.7% vs 0.00%). Across the 12 metrics below, BridgeBio Oncology Therapeutics, Inc leads on 6 and Prelude Therapeutics Incorporated on 6.

Valuation

Metric BBOT PRLD Biotechnology median
P/E n/m n/m 7.88
P/S n/m 17.02 11.47
P/B 0.98 2.85 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 10.26 10.73
Earnings yield (69.87%) (18.81%) (28.84%)
Free cash flow yield (47.93%) (8.73%) (23.03%)

Profitability

Metric BBOT PRLD Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (300.56%) 0.00%
Net margin 0.00% (269.75%) 0.00%
Free cash flow margin 0.00% (148.30%) 0.00%
Return on equity (252.10%) (57.73%) (57.72%)
Return on assets (96.69%) (39.76%) (49.22%)
Return on invested capital (127.66%) 0.00% 0.00%

Growth

Metric BBOT PRLD Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 99.93% 23.21% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BBOT PRLD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.69 4.07 4.73
Net debt to EBITDA 2.93 1.00 0.96

Dividend

Metric BBOT PRLD Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric BBOT PRLD Biotechnology median
Market cap 319.90m 318.42m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack